01—Abstract
Summary
Summary of the 8-K filed January 28, 2026. Cited figures are marked; the original filing is the authoritative source.
Halozyme Therapeutics, Inc. (Nasdaq: HALO) furnished an Item 2.02 Form 8-K on January 28, 2026, disclosing preliminary, unaudited 2025 results and raised 2026 and multi-year guidance.
For the twelve months ended December 31, 2025, the company estimates total revenue of $1,385 million to $1,400 milliona, royalty revenue of $865 million to $870 million, product sales of $372 million to $377 million, and collaboration revenue of $148 million to $153 million. The company states that royalty revenue growth is expected to exceed 50% year over year in 2025, with total revenue growth of 36% to 38% and royalty revenue growth of 51% to 52%. For 2026, Halozyme raised its guidance: total revenue of $1,710 million to $1,810 million (previously $1,430 million to $1,530 million), royalty revenue of $1,130 million to $1,170 million (previously $900 million to $940 million), adjusted EBITDA of $1,125 million to $1,205 million (previously $1,000 million to $1,080 million), and non-GAAP diluted EPS of $7.75 to $8.25 (previously $6.50 to $7.00).
The company notes that these figures include approximately $60 millionb of Hypercon and Surf Bio investment not included in prior guidance. Management said projected 2026 royalty revenue of more than $1 billion is one year earlier than previously projected. The company also disclosed that it acquired Surf Bio, Inc. in December 2025 for an upfront payment of $300 million, plus up to $100 million in milestone payments, for total consideration of up to $400 million.
The filing emphasizes that the preliminary 2025 estimates are subject to completion of financial close procedures and may vary materially from the results in the forthcoming Form 10-K. The Item 2.02 information is furnished, not filed.
02—Key points
Key Highlights
- Preliminary 2025 total revenue estimated at $1,385 million to $1,400 million, with royalty revenue of $865 million to $870 million.
- 2026 total revenue guidance raised to $1,710 million to $1,810 million from $1,430 million to $1,530 million.
- 2026 royalty revenue guidance raised to $1,130 million to $1,170 million from $900 million to $940 million, with projected growth of 30% to 35%.
- 2026 adjusted EBITDA guidance raised to $1,125 million to $1,205 million; non-GAAP diluted EPS guidance raised to $7.75 to $8.25 from $6.50 to $7.00.
- Guidance includes approximately $60 million of new Hypercon and Surf Bio investment not included in prior 2026 guidance.
- Acquired Surf Bio, Inc. in December 2025 for a $300 million upfront payment and up to $100 million in milestones, for total consideration of up to $400 million.
- Management expects 15 partner programs in development and three or more new drug delivery licensing agreements by the end of 2026.
03—Questions
Frequently Asked Questions
What were Halozyme's preliminary 2025 revenue results?
The company estimates 2025 total revenue of $1,385 million to $1,400 million and royalty revenue of $865 million to $870 million. It also estimates product sales of $372 million to $377 million and collaboration revenue of $148 million to $153 million. These figures are unaudited and may change during the financial close process.
How much did Halozyme raise its 2026 guidance?
Total revenue guidance increased to $1,710 million to $1,810 million from $1,430 million to $1,530 million. Royalty revenue guidance increased to $1,130 million to $1,170 million from $900 million to $940 million. Adjusted EBITDA guidance increased to $1,125 million to $1,205 million from $1,000 million to $1,080 million, and non-GAAP diluted EPS guidance increased to $7.75 to $8.25 from $6.50 to $7.00.
What did Halozyme pay to acquire Surf Bio?
Halozyme acquired Surf Bio, Inc. for an upfront payment of $300 million, subject to customary purchase price adjustments, plus up to $100 million in milestone payments tied to product development and regulatory approvals, for total consideration of up to $400 million. The company says the Surf Bio hyperconcentration technology is being developed for formulations of up to 500 mg/mL.
Do the preliminary 2025 figures present a risk of change?
Yes. The filing states that the preliminary estimates are subject to completion of financial and accounting close procedures, may be altered by further information, and could vary materially from the results reported in the Form 10-K for the year ended December 31, 2025. Investors are cautioned not to place undue reliance on this preliminary information.
What does the guidance include that was not in prior guidance?
The 2026 adjusted EBITDA and non-GAAP diluted EPS guidance include approximately $60 million of investment related to Hypercon and Surf Bio that was not included in prior 2026 guidance. The EPS guidance also does not consider the impact of potential future share repurchases.
04—Continue